Biocon has scrapped its plans to introduce generic versions of Novo Nordisk's Ozempic and Wegovy in China, citing intense ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

India’s health regulator has approved Eli Lilly’s pre-filled pen version of Mounjaro, expanding its availability across six ...

Health-care companies were more or less flat as traders rotated into higher risk sectors, amid optimism about Iran- and global trade negotiations. Walgreens Boots Alliance shares rose after it ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, ...

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.

A new study says common human typing errors can trip up artificial intelligence (AI) programs designed to aid health care ...

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

Novo Nordisk (NVO) has partnered with WeightWatchers (OTC:WGHTQ) to sell its obesity drug Wegovy days after exiting a similar ...